• Nexentis Technologies’ wholly owned subsidiary MitoCareX Bio completed initial AI-powered computational screening in its drug-discovery initiative with Boltz, launched in June 2026.
• Preliminary predictions require further computational analysis and experimental validation before any program can advance.
• MitoCareX retains control over its discovery programs and any small-molecule candidates advanced through the initiative.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290722PRIMZONEFULLFEED9856024) on October 29, 2026, and is solely responsible for the information contained therein.